Chronic lymphocytic leukemia treatment algorithm 2022.

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• The treatment landscape for chronic lymphocytic leukemia (CLL) has been revolutionized by novel oral targeted therapies and next-generation anti-CD20 monoclonal antibodies.
• These advancements have significantly improved outcomes for patients, including those with high-risk genetic abnormalities like del17p13 or TP53 mutations and unmutated IGHV genes.

Purpose of the Study:

• To summarize the current approach to managing chronic lymphocytic leukemia (CLL) from diagnosis through relapsed disease.
• To highlight the importance of personalized treatment selection based on disease characteristics, prior therapies, patient preferences, and comorbidities.

Main Methods:

• Review of current literature on CLL management strategies.
• Discussion of the role of novel oral targeted therapies (Bruton tyrosine kinase inhibitors, venetoclax) and anti-CD20 monoclonal antibodies (obinutuzumab).
• Emphasis on prognostic tools like the CLL-International Prognostic Index (CLL-IPI) for guiding treatment decisions.

Main Results:

• Introduction of highly effective oral targeted therapies and next-generation anti-CD20 monoclonal antibodies has transformed CLL treatment.
• These agents demonstrate efficacy even in patients with high-risk CLL features.
• The CLL-IPI is a validated tool for predicting time to first therapy in previously untreated patients.

Conclusions:

• Personalized treatment selection is crucial in CLL, considering disease biology, patient factors, and treatment sequencing.
• The evolving treatment landscape necessitates a comprehensive approach to CLL management.
• Effective strategies exist for managing CLL from initial diagnosis to relapsed or refractory disease.